Bioverativ Therapeutics Inc.

Syntonix Pharmaceuticals, Inc.

Lyndra Therapeutics, Inc.

Biogen Idec Hemophilia Inc.

Biogen Hemophilia Inc.

Syntomix Pharmaceuticals, Inc.

Susan C Low

Robert T Peters

Alan J Bitonti

Adam Robert Mezo

Daniel S Rivera

Jennifer A Dumont

Haiyan Jiang

Glenn Pierce

Jurg Sommer

Alvin Luk

Byron McKinney

Matt Ottmer

Karen Nugent

Lian Li

James I Wright

Stephen E Zale

Andrew Bellinger

Rosemary Lynn Kanasty

Nupura Bhise

Jung Hoon Yang

Alan J Bitoni

Bennett Carter

Byron Mckinney

Colin R Gardner

James Stattel

James McGivney

David Altreuter

Adam R Mezo

James M Stattel

Jurg M Sommer

The present invention provides methods of administering Factor VIII (processed FVIII, single chain FVIII, or a combination thereof); methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.

Factor VIII chimeric and hybrid polypeptides, and methods of use thereof

The invention provides gastric residence systems, or components of gastric residence system such as segments or elongate members of gastric residence systems, with release rate-modulating films and methods for making and using such systems. The release rate-modulating films provide good control over release of agents (such as therapeutic, diagnostic, or nutritional agents) present in the gastric residence system. The films also permit higher drug loading in the gastric residence systems and components of gastric residence systems while maintaining good control over release of agents. Some embodiments of the films can provide resistance against burst release of agent upon exposure to alcohol.

Gastric residence systems with release rate-modulating films

The invention provides gastric residence systems for administration of adamantane-class drugs or pharmaceutically acceptable salts thereof, such as memantine or pharmaceutically acceptable salts thereof, and methods for making and using such systems. The systems provide extended release of drug, reducing the frequency with which the drug must be administered to the patient. The gastric residence systems, or components of gastric residence system such as segments or elongate members of gastric residence systems, can have release rate-modulating films, which provide good control over release of adamantane-class drugs or pharmaceutically acceptable salts thereof present in the gastric residence system. Some embodiments of the films can provide resistance against burst release of adamantane-class drugs or pharmaceutically acceptable salts thereof upon exposure to alcohol.

Gastric residence systems for sustained delivery of adamantane-class drugs

The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.

Immunoglobulin chimeric monomer-dimer hybrids

The present invention provides methods of administering Factor VIII; methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.

Factor VIII-FC chimeric and hybrid polypeptides, and methods of use thereof

The present invention provides cell lines for producing single chain FVIII polypeptides, e.g., chimeric single chain FVIII polypeptides, methods of producing single chain FVIII polypeptides, single chain FVIII polypeptides, and methods of treating Hemophilia A with a single chain Factor VIII polypeptide.

Cell line expressing single chain factor VIII polypeptides and uses thereof

The present invention provides methods of reducing nonprocessed Factor VIII or a chimeric polypeptide comprising Factor VIII comprising co-transfecting in a host cell a polynucleotide encoding Factor VIII with a polynucleotide encoding a protein convertase, where the endogenous processing enzymes of the host cell are insufficient to convert all of the Factor VIII to its processed isoform; expressing a proprotein convertase from a second polynucleotide in the host cell; and reducing the nonprocessed Factor VIII by processing with said proprotein convertase.

Systems for factor VIII processing and methods thereof

Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereof

Growing community of inventors

Pepperell, MA, United States of America

Susan C Low